GRAIL, Inc.

GRAIL's Galleri® test is the only multi-cancer early detection (MCED) simple blood draw test widely commercially available to patients today. Galleri has the ability to detect a signal shared by 50+ cancers, 45+ of which do not have recommended screening tests currently available. Galleri also detects the cancer signal of origin with 93.4% accuracy, all with a low (0.4%) false positive rate. More than 7x as many cancers were detected when the Galleri® test was added to standard-of-care screenings based on Pathfinder II, the largest interventional MCED study in US history. GRAIL is the only solution provider currently offering a comprehensive program to employers for the early detection of multiple cancers with a single blood draw. With complex machine learning algorithms, GRAIL's technology platform is developed based on a rigorous scientific approach to cancer biology and years of research. Our population-scale clinical study program is the largest of its kind, with 380,000+ participants across completed and ongoing studies. To support and validate our technology, GRAIL partners with leading community and academic medical centers worldwide. The Galleri test was validated through clinical studies with 20+ institutions including Dana-Farber, University of Miami, etc.. Visit GRAIL's Clinical Studies (https://grail.com/clinical-studies/) webpage for more details.